On the public citation graph

Anti–CTLA-4 therapy requires an Fc domain for efficacy

https://doi.org/10.1073/pnas.1801524115
0 signed · 196 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1016/1074-7613(95)90125-6openalex-snapshot
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
inferredcites →https://doi.org/10.1016/j.cell.2015.04.016openalex-snapshot
Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
inferredcites →https://doi.org/10.1016/j.cell.2017.07.024openalex-snapshot
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
inferredcites →https://doi.org/10.1016/j.immuni.2017.03.013openalex-snapshot
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
inferredcites →https://doi.org/10.1016/j.jim.2007.04.008openalex-snapshot
Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs)
inferredcites →https://doi.org/10.1016/s1074-7613(00)80480-xopenalex-snapshot
Intracellular Trafficking of CTLA-4 and Focal Localization Towards Sites of TCR Engagement
inferredcites →https://doi.org/10.1021/acscentsci.5b00121openalex-snapshot
Use of 18F-2-Fluorodeoxyglucose to Label Antibody Fragments for Immuno-Positron Emission Tomography of Pancreatic Cancer
inferredcites →https://doi.org/10.1038/icb.2016.121openalex-snapshot
Role of Fc–FcγR interactions in the antitumor activity of therapeutic antibodies
inferredcites →https://doi.org/10.1038/nature13988openalex-snapshot
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
inferredcites →https://doi.org/10.1038/ncomms15373openalex-snapshot
Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells
inferredcites →https://doi.org/10.1038/nm.3746openalex-snapshot
Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations
inferredcites →https://doi.org/10.1038/nrc3239openalex-snapshot
The blockade of immune checkpoints in cancer immunotherapy
inferredcites →https://doi.org/10.1038/nri727openalex-snapshot
The B7–CD28 superfamily
inferredcites →https://doi.org/10.1038/s41467-017-00799-8openalex-snapshot
PD-L1 is an activation-independent marker of brown adipocytes
inferredcites →https://doi.org/10.1056/nejmoa1003466openalex-snapshot
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1104621openalex-snapshot
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1504030openalex-snapshot
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
inferredcites →https://doi.org/10.1073/pnas.0712237105openalex-snapshot
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
inferredcites →https://doi.org/10.1073/pnas.1502609112openalex-snapshot
Noninvasive imaging of immune responses
inferredcites →https://doi.org/10.1073/pnas.1604268113openalex-snapshot
Durable antitumor responses to CD47 blockade require adaptive immune stimulation
inferredcites →https://doi.org/10.1073/pnas.1617941114openalex-snapshot
Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab
inferredcites →https://doi.org/10.1073/pnas.1710776114openalex-snapshot
Localized CD47 blockade enhances immunotherapy for murine melanoma
inferredcites →https://doi.org/10.1073/pnas.90.8.3539openalex-snapshot
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
inferredcites →https://doi.org/10.1084/jem.190.3.355openalex-snapshot
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
inferredcites →https://doi.org/10.1084/jem.20101123openalex-snapshot
IAP inhibitors enhance co-stimulation to promote tumor immunity
inferredcites →https://doi.org/10.1084/jem.20130573openalex-snapshot
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
inferredcites →https://doi.org/10.1084/jem.20130579openalex-snapshot
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
inferredcites →https://doi.org/10.1084/jem.20141030openalex-snapshot
Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity
inferredcites →https://doi.org/10.1084/jem.20161950openalex-snapshot
Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells
inferredcites →https://doi.org/10.1093/nar/gkq395openalex-snapshot
3V: cavity, channel and cleft volume calculator and extractor
inferredcites →https://doi.org/10.1126/science.1160062openalex-snapshot
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
inferredcites →https://doi.org/10.1126/science.1255904openalex-snapshot
Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4
inferredcites →https://doi.org/10.1126/science.290.5492.816openalex-snapshot
Structure of Murine CTLA-4 and Its Role in Modulating T Cell Responsiveness
inferredcites →https://doi.org/10.1126/science.aaa4971openalex-snapshot
Neoantigens in cancer immunotherapy
inferredcites →https://doi.org/10.1126/science.aaa8172openalex-snapshot
The future of immune checkpoint therapy
inferredcites →https://doi.org/10.1126/scitranslmed.aal3604openalex-snapshot
In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
inferredcites →https://doi.org/10.1136/gutjnl-2014-308541openalex-snapshot
Early-onset Crohn’s disease and autoimmunity associated with a variant in CTLA-4
inferredcites →https://doi.org/10.1146/annurev-biochem-063011-092449openalex-snapshot
Nanobodies: Natural Single-Domain Antibodies
inferredcites →https://doi.org/10.1146/annurev-immunol-032414-112049openalex-snapshot
Coinhibitory Pathways in Immunotherapy for Cancer
inferredcites →https://doi.org/10.1146/annurev.immunol.021908.132544openalex-snapshot
Immune Therapy for Cancer
inferredcites →https://doi.org/10.1146/annurev.immunol.23.021704.115611openalex-snapshot
THE B7 FAMILY REVISITED
inferredcites →https://doi.org/10.1158/2326-6066.cir-13-0013openalex-snapshot
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
inferredcites →https://doi.org/10.1159/000453569openalex-snapshot
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
inferredcites →https://doi.org/10.1159/000455014openalex-snapshot
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
inferredcites →https://doi.org/10.1172/jci30966openalex-snapshot
MFG-E8–mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF
inferredcites →https://doi.org/10.1371/journal.pone.0109866openalex-snapshot
64Cu-DOTA-Anti-CTLA-4 mAb Enabled PET Visualization of CTLA-4 on the T-Cell Infiltrating Tumor Tissues
inferredcites →https://doi.org/10.2967/jnumed.109.070078openalex-snapshot
Nanobodies as Tools for In Vivo Imaging of Specific Immune Cell Types
inferredcites →https://doi.org/10.3389/fimmu.2017.01547openalex-snapshot
Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4133893openalex-extracted
Engineered E. coli for the Targeted Deposition of Therapeutic Payloads to Sites of Disease
inferred← citeshttps://doi.org/10.1002/adtp.202000018openalex-snapshot
ImmunoPET Imaging of TIM‐3 in Murine Melanoma Models
inferred← citeshttps://doi.org/10.1002/advs.202200064openalex-snapshot
In Vivo Click Chemistry Enables Multiplexed Intravital Microscopy
inferred← citeshttps://doi.org/10.1002/bab.1724openalex-snapshot
Preparation and anti‐tumor efficiency evaluation of bacterial magnetosome–anti‐4‐1BB antibody complex: Bacterial magnetosome as antibody carriers isolated from Magnetospirillum gryphiswaldense
inferred← citeshttps://doi.org/10.1002/psp4.12800openalex-snapshot
Quantitative systems pharmacology modeling provides insight into inter‐mouse variability of Anti‐CTLA4 response
inferred← citeshttps://doi.org/10.1002/viw.20260027openalex-snapshot
Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine
inferred← citeshttps://doi.org/10.1007/s00259-020-04784-0openalex-snapshot
Development and characterization of CD54-targeted immunoPET imaging in solid tumors
inferred← citeshttps://doi.org/10.1007/s00259-025-07441-6openalex-snapshot
ImmunoPET imaging of c-Met using a nanobody-based tracer [68Ga]Ga-NOTA-PFCM01 in pancreatic ductal adenocarcinoma models and non-human primates
inferred← citeshttps://doi.org/10.1007/s00262-022-03170-zopenalex-snapshot
Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy
inferred← citeshttps://doi.org/10.1007/s00262-023-03385-8openalex-snapshot
Therapeutic potential of FLT4-targeting peptide in acute myeloid leukemia
inferred← citeshttps://doi.org/10.1007/s00262-024-03671-zopenalex-snapshot
Characterization of a novel anti-PVRIG antibody with Fc-competent function that exerts strong antitumor effects via NK activation in preclinical models
inferred← citeshttps://doi.org/10.1007/s00262-024-03794-3openalex-snapshot
Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs
inferred← citeshttps://doi.org/10.1007/s11894-020-0752-zopenalex-snapshot
Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives
inferred← citeshttps://doi.org/10.1007/s11912-021-01095-xopenalex-snapshot
Cytokines: Signalling Improved Immunotherapy?
inferred← citeshttps://doi.org/10.1007/s12032-023-02289-yopenalex-snapshot
Evaluation of regulatory T-cells in cancer immunotherapy: therapeutic relevance of immune checkpoint inhibition
inferred← citeshttps://doi.org/10.1007/s12033-023-00885-xopenalex-snapshot
Application of Computational Techniques in Antibody Fc-Fused Molecule Design for Therapeutics
inferred← citeshttps://doi.org/10.1007/s12038-020-0020-2openalex-snapshot
T cell costimulation, checkpoint inhibitors and anti-tumor therapy
inferred← citeshttps://doi.org/10.1016/b978-0-12-824375-6.00013-8openalex-snapshot
Checkpoint inhibition in the fight against cancer: NK cells have some to say in it
inferred← citeshttps://doi.org/10.1016/b978-0-323-90949-5.00013-9openalex-snapshot
Image-guided cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/bs.acr.2019.05.001openalex-snapshot
Expression of costimulatory and inhibitory receptors in FoxP3+ regulatory T cells within the tumor microenvironment: Implications for combination immunotherapy approaches
inferred← citeshttps://doi.org/10.1016/bs.apcsb.2024.10.014openalex-snapshot
From antibodies to nanobodies: The next frontier in cancer theranostics for solid tumors
inferred← citeshttps://doi.org/10.1016/bs.ircmb.2022.03.010openalex-snapshot
Emerging applications of nanobodies in cancer therapy
inferred← citeshttps://doi.org/10.1016/bs.ircmb.2023.03.003openalex-snapshot
Novel technologies for applying immune checkpoint blockers
inferred← citeshttps://doi.org/10.1016/j.addr.2022.114239openalex-snapshot
Imaging and therapeutic targeting of the tumor immune microenvironment with biologics
inferred← citeshttps://doi.org/10.1016/j.bbcan.2023.188862openalex-snapshot
Proteins and their functionalization for finding therapeutic avenues in cancer: Current status and future prospective
inferred← citeshttps://doi.org/10.1016/j.biomaterials.2019.119469openalex-snapshot
The potentiated checkpoint blockade immunotherapy by ROS-responsive nanocarrier-mediated cascade chemo-photodynamic therapy
inferred← citeshttps://doi.org/10.1016/j.canlet.2019.05.003openalex-snapshot
Treg-mediated acquired resistance to immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1016/j.canlet.2022.215896openalex-snapshot
Molecular imaging of immune checkpoints in oncology: Current and future applications
inferred← citeshttps://doi.org/10.1016/j.canrad.2023.06.017openalex-snapshot
Lymphopénie radio-induite : les lymphocytes comme nouvel organe à risque
inferred← citeshttps://doi.org/10.1016/j.ccell.2018.05.005openalex-snapshot
Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens
inferred← citeshttps://doi.org/10.1016/j.chom.2023.03.007openalex-snapshot
Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut
inferred← citeshttps://doi.org/10.1016/j.ebiom.2022.103840openalex-snapshot
Immune checkpoint blockade in HIV
inferred← citeshttps://doi.org/10.1016/j.ejca.2023.113501openalex-snapshot
The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?
inferred← citeshttps://doi.org/10.1016/j.ejps.2021.105941openalex-snapshot
Dinitrophenol-mediated modulation of an anti-PD-L1 VHH for Fc-dependent effector functions and prolonged serum half-life
inferred← citeshttps://doi.org/10.1016/j.freeradbiomed.2022.02.031openalex-snapshot
Nanobodies as molecular imaging probes
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2025.140760openalex-snapshot
Algal proteins and bioactive peptides: Sustainable nutrition for human health
inferred← citeshttps://doi.org/10.1016/j.intimp.2021.107553openalex-snapshot
Expression of PD-L1 in EBV-associated malignancies
inferred← citeshttps://doi.org/10.1016/j.iotech.2020.03.001openalex-snapshot
Molecular imaging for cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.iotech.2020.07.001openalex-snapshot
Nanobodies as non-invasive imaging tools
inferred← citeshttps://doi.org/10.1016/j.jconrel.2020.08.021openalex-snapshot
Antibody and antibody fragments for cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.jid.2018.11.028openalex-snapshot
Targeted Delivery of TNF Potentiates the Antibody-Dependent Cell-Mediated Cytotoxicity of an Anti-Melanoma Immunoglobulin
inferred← citeshttps://doi.org/10.1016/j.jim.2023.113425openalex-snapshot
In silico engineering a CD80 variant with increased affinity to CTLA-4 and decreased affinity to CD28 for optimized cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2020.107786openalex-snapshot
PET imaging of immune checkpoint proteins in oncology
inferred← citeshttps://doi.org/10.1016/j.prp.2022.154241openalex-snapshot
Recent progress in cancer immunotherapy: Overview of current status and challenges
inferred← citeshttps://doi.org/10.1016/j.semcancer.2021.10.003openalex-snapshot
Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation
inferred← citeshttps://doi.org/10.1016/j.semcancer.2022.02.016openalex-snapshot
Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials
inferred← citeshttps://doi.org/10.1016/j.smim.2020.101425openalex-snapshot
Nanobodies in cancer
inferred← citeshttps://doi.org/10.1016/j.smim.2021.101473openalex-snapshot
Checkpoint blockade toxicities: Insights into autoimmunity and treatment
inferred← citeshttps://doi.org/10.1016/j.tranon.2019.12.010openalex-snapshot
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1016/j.xcrm.2025.102141openalex-snapshot
Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade
inferred← citeshttps://doi.org/10.1021/acs.chemrev.9b00738openalex-snapshot
ImmunoPET: Concept, Design, and Applications
inferred← citeshttps://doi.org/10.1021/acschembio.9b00743openalex-snapshot
An Immune-Stimulatory Helix–Loop–Helix Peptide: Selective Inhibition of CTLA-4–B7 Interaction
inferred← citeshttps://doi.org/10.1021/jacs.2c01932openalex-snapshot
Palladium-Mediated Incorporation of Carboranes into Small Molecules, Peptides, and Proteins
inferred← citeshttps://doi.org/10.1038/s41419-023-06391-xopenalex-snapshot
Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy
inferred← citeshttps://doi.org/10.1038/s41551-025-01447-zopenalex-snapshot
Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy
inferred← citeshttps://doi.org/10.1038/s41568-025-00869-wopenalex-snapshot
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
inferred← citeshttps://doi.org/10.1038/s41598-021-00325-3openalex-snapshot
Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients
inferred← citeshttps://doi.org/10.1038/s42003-023-05332-wopenalex-snapshot
SARS-CoV-2 antibodies recognize 23 distinct epitopic sites on the receptor binding domain
inferred← citeshttps://doi.org/10.1039/d1cb00023copenalex-snapshot
Nanobodies as in vivo , non-invasive, imaging agents
inferred← citeshttps://doi.org/10.1073/pnas.2200879119openalex-snapshot
An anti-CTLA-4 heavy chain–only antibody with enhanced T reg depletion shows excellent preclinical efficacy and safety profile
inferred← citeshttps://doi.org/10.1073/pnas.2300895120openalex-snapshot
Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies
inferred← citeshttps://doi.org/10.1073/pnas.2424251122openalex-snapshot
Prostaglandin E 2 -EP2/EP4 signaling induces the tumor-infiltrating Treg phenotype for tumor growth
inferred← citeshttps://doi.org/10.1080/13543784.2019.1559297openalex-snapshot
CTLA4 antagonists in phase I and phase II clinical trials, current status and future perspectives for cancer therapy
inferred← citeshttps://doi.org/10.1080/14740338.2022.2020243openalex-snapshot
Nobel Prize for immune checkpoint inhibitors, understanding the immunological switching between immunosuppression and autoimmunity
inferred← citeshttps://doi.org/10.1080/17425247.2022.2093853openalex-snapshot
Recent progress in antibody-based therapeutics for triple-negative breast cancer
inferred← citeshttps://doi.org/10.1080/19420862.2020.1725365openalex-snapshot
A functional antibody cross-reactive to both human and murine cytotoxic T-lymphocyte-associated protein 4 via binding to an N-glycosylation epitope
inferred← citeshttps://doi.org/10.1084/jem.20241217openalex-snapshot
Inhibitory receptor agonists: Emerging strategies in immune modulation
inferred← citeshttps://doi.org/10.1093/immadv/ltae006openalex-snapshot
Advancements in nuclear imaging using radiolabeled nanobody tracers to support cancer immunotherapy
inferred← citeshttps://doi.org/10.1093/immadv/ltaf008openalex-snapshot
CTLA-4—two pathways to anti-tumour immunity?
inferred← citeshttps://doi.org/10.1093/pcmedi/pbab027openalex-snapshot
Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives
inferred← citeshttps://doi.org/10.1098/rsob.190235openalex-snapshot
Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH
inferred← citeshttps://doi.org/10.1101/2021.07.12.452090openalex-snapshot
Lack of blocking activity in anti-CTLA-4 antibodies reduces toxicity, but not anti-tumor efficacy
inferred← citeshttps://doi.org/10.1101/2024.01.04.23300616openalex-snapshot
Depletion of effector regulatory T cells drives major response to induction dual immune checkpoint blockade
inferred← citeshttps://doi.org/10.1111/bph.16313openalex-snapshot
The impact of Foxp3 + regulatory T‐cells on CD8 + T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1111/imm.13323openalex-snapshot
Pouring petrol on the flames: Using oncolytic virotherapies to enhance tumour immunogenicity
inferred← citeshttps://doi.org/10.1111/imr.13239openalex-snapshot
Gastrointestinal mucosal toxicities from immune checkpoint inhibitors: Current understanding and future directions
inferred← citeshttps://doi.org/10.1111/imr.13381openalex-snapshot
Single domain antibody: Development and application in biotechnology and biopharma
inferred← citeshttps://doi.org/10.1126/science.adh8342openalex-snapshot
Microbiota-dependent activation of CD4 + T cells induces CTLA-4 blockade–associated colitis via Fcγ receptors
inferred← citeshttps://doi.org/10.1126/sciimmunol.add8005openalex-snapshot
Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy
inferred← citeshttps://doi.org/10.1126/sciimmunol.adg9459openalex-snapshot
An armed anti-immunoglobulin light chain nanobody protects mice against influenza A and B infections
inferred← citeshttps://doi.org/10.1136/jitc-2019-000413openalex-snapshot
The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a
inferred← citeshttps://doi.org/10.1136/jitc-2021-003488openalex-snapshot
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’ tumors
inferred← citeshttps://doi.org/10.1158/2159-8290.cd-24-1390openalex-snapshot
Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade
inferred← citeshttps://doi.org/10.1158/2326-6066.cir-18-0386openalex-snapshot
Anti–CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control
inferred← citeshttps://doi.org/10.1158/2326-6066.cir-23-0389openalex-snapshot
FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
inferred← citeshttps://doi.org/10.1177/1534735419846379openalex-snapshot
Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota
inferred← citeshttps://doi.org/10.1186/s12943-020-01234-1openalex-snapshot
Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects
inferred← citeshttps://doi.org/10.1186/s12943-021-01329-3openalex-snapshot
mRNA in cancer immunotherapy: beyond a source of antigen
inferred← citeshttps://doi.org/10.1186/s12957-023-03212-5openalex-snapshot
Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1186/s13045-019-0721-xopenalex-snapshot
Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy
inferred← citeshttps://doi.org/10.1186/s13045-021-01134-xopenalex-snapshot
Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities
inferred← citeshttps://doi.org/10.1186/s40425-019-0570-8openalex-snapshot
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
inferred← citeshttps://doi.org/10.1186/s41181-019-0078-zopenalex-snapshot
Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer
inferred← citeshttps://doi.org/10.1369/0022155419882292openalex-snapshot
CTLA-4 Immunohistochemistry and Quantitative Image Analysis for Profiling of Human Cancers
inferred← citeshttps://doi.org/10.1515/oncologie-2023-0412openalex-snapshot
Immunotherapy in hepatocellular carcinoma: an overview of immune checkpoint inhibitors, drug resistance, and adverse effects
inferred← citeshttps://doi.org/10.15581/10171/67876openalex-snapshot
Tailoring the bioactivities of IL-12 for cancer immunotherapy with mRNA-based technology: from immunocytokines to armored T cell transfer
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1233122/v1openalex-snapshot
Engineered E. coli for the targeted deposition of therapeutic payloads to sites of disease
inferred← citeshttps://doi.org/10.2139/ssrn.5400228openalex-snapshot
Antitumor Effects of a Peptide Sequences based on Gramicidin Molecule as Possible Inhibitor of PD-1 and PD-L-1
inferred← citeshttps://doi.org/10.2147/btt.s166310openalex-snapshot
Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy
inferred← citeshttps://doi.org/10.2147/ijn.s480939openalex-snapshot
Fusing a Novel Anti-CTLA-4 Nanobody to the IgG1 Fc Region Strengthens Its Ability to Induce CD8+ T Cell-Mediated Immune Responses Against Solid Tumors
inferred← citeshttps://doi.org/10.26717/bjstr.2021.40.006490openalex-snapshot
"The Application of Nanobody in Non-invasive Imaging of Cancers"
inferred← citeshttps://doi.org/10.32607/actanaturae.11102openalex-snapshot
Mechanisms of Action of the PGLYRP1/Tag7 Protein in Innate and Acquired Immunity
inferred← citeshttps://doi.org/10.3389/fams.2022.993581openalex-snapshot
Elaborating on anti CTLA-4 mechanisms of action using an agent-based modeling approach
inferred← citeshttps://doi.org/10.3389/fbioe.2020.00141openalex-snapshot
Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors
inferred← citeshttps://doi.org/10.3389/fimmu.2018.02553openalex-snapshot
CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells
inferred← citeshttps://doi.org/10.3389/fimmu.2018.02559openalex-snapshot
Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma
inferred← citeshttps://doi.org/10.3389/fimmu.2019.00805openalex-snapshot
IgG and Fcγ Receptors in Intestinal Immunity and Inflammation
inferred← citeshttps://doi.org/10.3389/fimmu.2019.02453openalex-snapshot
T Regulatory Cells and Priming the Suppressive Tumor Microenvironment
inferred← citeshttps://doi.org/10.3389/fimmu.2020.00168openalex-snapshot
The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass
inferred← citeshttps://doi.org/10.3389/fimmu.2020.00634openalex-snapshot
IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses
inferred← citeshttps://doi.org/10.3389/fimmu.2020.01633openalex-snapshot
Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies
inferred← citeshttps://doi.org/10.3389/fimmu.2020.573405openalex-snapshot
Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation
inferred← citeshttps://doi.org/10.3389/fimmu.2024.1491508openalex-snapshot
Machine learning based anoikis signature predicts personalized treatment strategy of breast cancer
inferred← citeshttps://doi.org/10.3389/fimmu.2026.1847526openalex-snapshot
Rethinking biomarker strategy in gastric cancer immunotherapy: from tumor to host
inferred← citeshttps://doi.org/10.3389/fmed.2022.916693openalex-snapshot
ImmunoPET: Antibody-Based PET Imaging in Solid Tumors
inferred← citeshttps://doi.org/10.3389/fonc.2020.01182openalex-snapshot
Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics
inferred← citeshttps://doi.org/10.3389/fonc.2021.737497openalex-snapshot
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
inferred← citeshttps://doi.org/10.3389/fonc.2023.1107631openalex-snapshot
Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application
inferred← citeshttps://doi.org/10.3389/fonc.2023.981247openalex-snapshot
Targeting breast cancer stem cells directly to treat refractory breast cancer
inferred← citeshttps://doi.org/10.3389/fpls.2023.1149455openalex-snapshot
Antitumor effect of plant-produced anti-CTLA-4 monoclonal antibody in a murine model of colon cancer
inferred← citeshttps://doi.org/10.3390/antib8010013openalex-snapshot
Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer
inferred← citeshttps://doi.org/10.3390/bioengineering9080360openalex-snapshot
Simultaneous Maturation of Single Chain Antibody Stability and Affinity by CHO Cell Display
inferred← citeshttps://doi.org/10.3390/biom10121661openalex-snapshot
Picomolar SARS-CoV-2 Neutralization Using Multi-Arm PEG Nanobody Constructs
inferred← citeshttps://doi.org/10.3390/biom10121695openalex-snapshot
Nanobodies as Versatile Tool for Multiscale Imaging Modalities
inferred← citeshttps://doi.org/10.3390/biom11050637openalex-snapshot
Nanobodies for Medical Imaging: About Ready for Prime Time?
inferred← citeshttps://doi.org/10.3390/biom9100548openalex-snapshot
Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use
inferred← citeshttps://doi.org/10.3390/cancers13010043openalex-snapshot
Immunotherapy in Solid Tumors and Gut Microbiota: The Correlation—A Special Reference to Colorectal Cancer
inferred← citeshttps://doi.org/10.3390/cancers14061580openalex-snapshot
Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy
inferred← citeshttps://doi.org/10.3390/cancers17193172openalex-snapshot
Regulatory T Cells in Invasive Breast Cancer: Prognosis, Mechanisms and Therapy
inferred← citeshttps://doi.org/10.3390/cancers18193099openalex-snapshot
Preclinical–Clinical Discrepancies in Immune Checkpoint Inhibitor Efficacy for Triple-Negative Breast Cancer: Disease Stage, Antibody Properties, Biomarker Alignment, and Model Limitations
inferred← citeshttps://doi.org/10.3390/diagnostics11091530openalex-snapshot
Radiolabeling Strategies of Nanobodies for Imaging Applications
inferred← citeshttps://doi.org/10.3390/ijms21238984openalex-snapshot
Overcoming Immune Evasion in Melanoma
inferred← citeshttps://doi.org/10.3390/ijms22063081openalex-snapshot
The Role of CTLA4 and Its Polymorphisms in Solid Organ and Haematopoietic Stem Cell Transplantation
inferred← citeshttps://doi.org/10.3390/ijms231810367openalex-snapshot
Finding the Right Heavy Chains for Immunostimulatory Antibodies
inferred← citeshttps://doi.org/10.3390/ijms27104630openalex-snapshot
Regulatory T Cells in Hepatocellular Carcinoma: Spatial Niches, Biomarkers, and Clinical Implications
inferred← citeshttps://doi.org/10.3390/jcm8101667openalex-snapshot
NK Cell-Fc Receptors Advance Tumor Immunotherapy
inferred← citeshttps://doi.org/10.3390/pharmaceutics12070663openalex-snapshot
Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy
inferred← citeshttps://doi.org/10.3892/ijo.2020.5099openalex-snapshot
Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review)
inferred← citeshttps://doi.org/10.4049/jimmunol.2300040openalex-snapshot
Early T Cell Infiltration Correlates with Anti-CTLA4 Treatment Response in Murine Cancer Models
inferred← citeshttps://doi.org/10.5812/tms.114888openalex-snapshot
The Potential Applicability of Single-Domain Antibodies (VHH): From Checkpoint Blockade to Infectious Disease Therapy
inferred← citeshttps://doi.org/10.64898/2026.03.22.711591openalex-snapshot
Capsid structures of Atlas viruses reveal an engineerable nanoparticle scaffold
inferred← citeshttps://doi.org/10.70675/0846fa89zb47dz41afzaa8bz1aba36466f1dopenalex-snapshot
Le clivage de la région charnière des anticorps monoclonaux thérapeutiques : relation entre leur structure et la sensibilité aux protéases, conséquences fonctionnelles et développement d'un nanobody spécifique des formes clivées
inferred← citeshttps://doi.org/10.70675/e7695737z26a3z4747zafafzb19e3e74372bopenalex-snapshot
Efficacy and synergy of low-dose radiotherapy combined with anti-PD-L1 based immunotherapy
inferred← citeshttps://doi.org/10.70675/edef1ab4z23a8z41faz98edz80fe61eeb69copenalex-snapshot
Generation of a proteomic platform of high processivity for the identification and characterization of recombinant VHHs against CD105
inferred← citeshttps://doi.org/10.70675/ff8cb58bzc391z43f8zbd32zc8c4b2cdc725openalex-snapshot
Identification of Biomarkers Associated With the Combination of Immunotherapy and Anti-Angiogenic Drugs in the Treatment of Mesothelioma : Translational Analyses of the PEMBIB Clinical Trial Combining the Anti-PD1 Monoclonal Antibody Embrolizumab and the Anti-Angiogenic Tyrosine Kinase Inhibitor…
inferred← citeshttps://doi.org/10.7150/ntno.50860openalex-snapshot
Noninvasive Imaging of Cancer Immunotherapy
inferred← citeshttps://doi.org/10.7150/thno.30577openalex-snapshot
Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy
inferred← citeshttps://doi.org/10.7150/thno.34941openalex-snapshot
Theranostics in immuno-oncology using nanobody derivatives
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.